364782-34-3 | Cinacalcet, HCl

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$6.00	$4.00
10mg	98%	in stock	$8.00	$6.00
50mg	98%	in stock	$10.00	$7.00
100mg	98%	in stock	$15.00	$11.00
250mg	98%	in stock	$24.00	$17.00
1g	98%	in stock	$58.00	$41.00
5g	95%	in stock	$277.00	$194.00
10g	95%	in stock	$492.00	$345.00
25g	95%	in stock	$984.00	$689.00

Description

• Catalog Number: AI48975
• Chemical Name: Cinacalcet, HCl
• CAS Number: 364782-34-3
• Molecular Formula: C22H22ClF3N
• Molecular Weight: 393.8729
• MDL Number: MFCD08067750
• SMILES: C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F.[Cl-].[H+]

Computed Properties

• Complexity: 422
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6

Literature

• Why are most phospholipidosis inducers also hERG blockers?

  Archives of toxicology 20171201

• Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics.

  British journal of pharmacology 20150101

• Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators.

  Endocrinology 20130301

• [Potentialisation of hyperkalemia effects by cinacalcet-induced hypocalcemia on dialysis].

  Nephrologie & therapeutique 20121101

• Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats.

  Journal of hypertension 20121101

• Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats.

  Calcified tissue international 20121101

• Allosteric agonists of the calcium receptor (CaR): fluorine and SF5 analogues of cinacalcet.

  Organic & biomolecular chemistry 20121021

• Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.

  International urology and nephrology 20121001

• An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.

  Pediatric nephrology (Berlin, Germany) 20121001

• [Cinacalcet hydrochloride and phosphate metabolism].

  Clinical calcium 20121001

• Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.

  Transplantation proceedings 20121001

• Withdrawal of cinacalcet at the time of renal transplantation is not a risk factor for allograft calcifications in the early posttransplantation period.

  Transplantation proceedings 20121001

• Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.

  Clinical journal of the American Society of Nephrology : CJASN 20120907

• Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120801

• Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20120801

• MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.

  European journal of endocrinology 20120801

• Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study.

  Clinical nephrology 20120801

• Treatment of secondary hyperparathyroidism with parathyroidectomy instead of cinacalcet: time to pick the low-hanging fruit?

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20120801

• Hyperparathyroidism in chronic kidney disease: complexities within the commonplace.

  Clinical medicine (London, England) 20120801

• Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies.

  Transplantation 20120715

• Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.

  Journal of endocrinological investigation 20120701

• Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120701

• Maximal conservative therapy of calcific uremic ateriolopathy.

  Clinical nephrology 20120701

• Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.

  Clinical nephrology 20120701

• [Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].

  Clinical calcium 20120701

• [Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].

  Clinical calcium 20120701

• [Questions about the ADVANCE study].

  Nephrologie & therapeutique 20120601

• Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601

• Deal watch: Amgen builds secondary hyperparathyroidism [corrected] pipeline.

  Nature reviews. Drug discovery 20120601

• [Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].

  Medicina clinica 20120526

• Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.

  Annals of surgical oncology 20120501

• Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120501

• Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120501

• Cinacalcet: will it play a role in reducing cardiovascular events?

  Future cardiology 20120501

• Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.

  Clinical therapeutics 20120501

• [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].

  Medicina clinica 20120407

• Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.

  Clinical and experimental nephrology 20120401

• Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.

  Hemodialysis international. International Symposium on Home Hemodialysis 20120401

• Antilipolytic effect of calcimimetics depends on the allelic variant of calcium-sensing receptor gene polymorphism rs1042636 (Arg990Gly).

  European journal of human genetics : EJHG 20120401

• A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.

  Clinical journal of the American Society of Nephrology : CJASN 20120401

• [Calcimimetic drugs in stage 3-5 chronic kidney disease].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20120401

• Determination of cinacalcet hydrochloride in human plasma by liquid chromatography-tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20120305

• Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients.

  Nephrology (Carlton, Vic.) 20120301

• Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.

  Endocrinology 20120301

• A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.

  Applied health economics and health policy 20120301

• Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism.

  Pediatrics 20120301

• [Cinacalcet impact on calcium homeostasis and bone remodeling in 13 renal transplanted patients with hyperparathyroidism and hypercalcaemia].

  Nephrologie & therapeutique 20120201

• Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

• [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• [The value of selective parathyroid venous sampling for localizing occult parathyroid adenomas].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101

• Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.

  Clinical transplantation 20120101

• Immunohistochemical and functional studies on calcium-sensing receptors in rat uterine smooth muscle.

  Clinical and experimental pharmacology & physiology 20120101

• Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.

  Nephrology (Carlton, Vic.) 20120101

• Update on the use of cinacalcet in the management of primary hyperparathyroidism.

  Journal of endocrinological investigation 20120101

• Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.

  The Netherlands journal of medicine 20120101

• Short-term use of cinacalcet in children on regular hemodialysis.

  Arab journal of nephrology and transplantation 20120101

• Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.

  Journal of medical economics 20120101

• A novel use of cinacalcet to distinguish primary hyperparathyroidism from hypercalcemia of malignancy in a patient with a low-normal parathyroid hormone concentration.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• The prevalence and cost of unapproved uses of top-selling orphan drugs.

  PloS one 20120101

• Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20120101

• Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report.

  Polskie Archiwum Medycyny Wewnetrznej 20120101

• Effects of cinacalcet in renal transplant patients with hyperparathyroidism.

  American journal of nephrology 20120101

• Kokumi substances, enhancers of basic tastes, induce responses in calcium-sensing receptor expressing taste cells.

  PloS one 20120101

• Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

  International journal of biological sciences 20120101

• Calcimimetics in peritoneal dialysis patients.

  Contributions to nephrology 20120101

• Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.

  American journal of nephrology 20120101

• Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.

  Artificial organs 20111201

• Multi-intervention management of calciphylaxis: a report of 7 cases.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201

• Complete clearance of calciphylaxis following combined treatment with cinacalcet and sodium thiosulfate.

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20111201

• Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20111201

• [Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].

  Clinical calcium 20111201

• Calciphylaxis: a severe complication of renal disease.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20111108

• Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.

  Nephrology (Carlton, Vic.) 20111101

• Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism.

  Transplantation 20111027

• Two cases of acute renal hemorrhage undergoing maintenance hemodialysis after concurrent administration of cinacalcet.

  Clinical and experimental nephrology 20111001

• Development and prevention of morphologic and ultrastructural changes in uremia-induced hyperplastic parathyroid gland.

  Ultrastructural pathology 20111001

• Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism.

  Clinical nephrology 20111001

• Mineral and bone disorders in children with chronic kidney disease.

  Nature reviews. Nephrology 20110927

• Quantification of cinacalcet by LC-MS/MS using liquid-liquid extraction from 50 μL of plasma.

  Journal of pharmaceutical and biomedical analysis 20110910

• Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.

  Journal of clinical pathology 20110901

• Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20110901

• Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

  Clinical journal of the American Society of Nephrology : CJASN 20110901

• Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

  PharmacoEconomics 20110901

• Refractory calciphylaxis.

  American journal of surgery 20110901

• Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.

  Clinical nephrology 20110901

• A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.

  Clinical and experimental nephrology 20110801

• Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.

  Clinical nephrology 20110801

• Cinacalcet for the treatment of primary hyperparathyroidism.

  American journal of therapeutics 20110701

• [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].

  Nephrologie & therapeutique 20110701

• Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.

  Calcified tissue international 20110701

• Indirect reversed-phase high-performance liquid chromatographic and direct thin-layer chromatographic enantioresolution of (R,S)-Cinacalcet.

  Biomedical chromatography : BMC 20110601

• Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110601

• Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

  Endocrine 20110601

• Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.

  Endocrine 20110601

• Tertiary hyperparathyroidism resistant to cinacalcet treatment.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110601

• Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110601

• A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20110501

• Naphthalene triplet excited state as a probe for the assessment of drug distribution in binary protein systems.

  The journal of physical chemistry. B 20110421

• The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401

• Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic.

  Nature reviews. Nephrology 20110401

• Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet.

  The Journal of clinical endocrinology and metabolism 20110401

• [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].

  Nephrologie & therapeutique 20110401

• Clinical utilization of cinacalcet in hypercalcemic conditions.

  Expert opinion on drug metabolism & toxicology 20110401

• Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401

• [Morphological analysis of bone dynamics and metabolic bone disease. A case report of recurrent renal hyperparathyroidism].

  Clinical calcium 20110401

• Medical treatment of primary, secondary, and tertiary hyperparathyroidism.

  Current drug safety 20110401

• The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.

  Transplantation 20110315

• Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.

  Clinical nephrology 20110301

• Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation.

  Clinical nephrology 20110301

• Enhanced photosafety of cinacalcet upon complexation with serum albumin.

  The journal of physical chemistry. B 20110210

• Vascular actions of calcimimetics: role of Ca²(+) -sensing receptors versus Ca²(+) influx through L-type Ca²(+) channels.

  British journal of pharmacology 20110201

• Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrow.

  Blood 20110127

• Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.

  Journal of nephrology 20110101

• Therapeutic management of post-kidney transplant hyperparathyroidism.

  Clinical transplantation 20110101

• Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

  Nephron. Clinical practice 20110101

• Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

  The Journal of clinical endocrinology and metabolism 20110101

• Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice.

  Nephron. Clinical practice 20110101

• [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].

  Deutsche medizinische Wochenschrift (1946) 20110101

• Calcific uremic arteriolopathy while on cinacalcet.

  Journal of postgraduate medicine 20110101

• Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.

  Wiener klinische Wochenschrift 20110101

• Cinacalcet in the treatment of hypercalcaemia and control of hyperparathyroidism due to ectopic parathyroid glands.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation.

  Kidney & blood pressure research 20110101

• [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110101

• Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors.

  Journal of cutaneous medicine and surgery 20110101

• [Use of cinacalcet in clinical practice for the treatment of secondary hyperparathyroidism: analysis of the Italian data of the ECHO study].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20110101

• New insights into the role of calcium-sensing receptor activation.

  Journal of nephrology 20110101

• Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.

  Blood purification 20110101

• Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report.

  Renal failure 20110101

• Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?

  Seminars in dialysis 20110101

• Regression of vascular calcification in a patient treated with cinacalcet: a case report.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Multidisciplinary treatment. A therapeutic option to treat calciphylaxis.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Association of cinacalcet adherence and costs in patients on dialysis.

  Journal of medical economics 20110101

• Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, improve arterial stiffness in patients on continuous ambulatory peritoneal dialysis?

  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20110101

• [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20110101

• Cinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy.

  BMJ case reports 20110101

• Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

  Clinical journal of the American Society of Nephrology : CJASN 20101201

• The bone and mineral disorder of children undergoing chronic peritoneal dialysis.

  Kidney international 20101201

• Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20101201

• Continuation of cinacalcet immediately after renal transplantation: a prospective cohort study.

  Clinical nephrology 20101201

• The challenges of cost-effectiveness analyses for the clinician.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20101201

• Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20101201

• An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective.

  Surgery 20101201

• Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients.

  Transplantation proceedings 20101201

• Long-term results of surgery for lithium-associated hyperparathyroidism (Br J Surg 2010; 97:1680-1685).

  The British journal of surgery 20101101

• Fetuin-mineral complex reflects extraosseous calcification stress in CKD.

  Journal of the American Society of Nephrology : JASN 20101101

• Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism.

  Transplantation proceedings 20101101

• Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis.

  Journal of the American Society of Nephrology : JASN 20101001

• Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo.

  American journal of physiology. Regulatory, integrative and comparative physiology 20101001

• Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols.

  Bioorganic & medicinal chemistry letters 20101001

• Cinacalcet and cardiovascular mortality in hemodialysis patients.

  Kidney international 20101001

• Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.

  Hemodialysis international. International Symposium on Home Hemodialysis 20101001

• Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia.

  Pediatric nephrology (Berlin, Germany) 20100901

• Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

  Kidney international 20100901

• Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis.

  Nutrition (Burbank, Los Angeles County, Calif.) 20100901

• Lead-time bias in studies of cinacalcet prescriptions.

  Kidney international 20100901

• Cinacalcet effect on severe hyperparathyroidism.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20100901

• Evaluation of cinacalcet HCl treatment after kidney transplantation.

  Transplantation proceedings 20100901

• 'Real-World' use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study.

  Clinical nephrology 20100901

• Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).

  Biochemical pharmacology 20100801

• Effects of cinacalcet on vascular calcification in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100801

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].

  Clinical calcium 20100701

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].

  Clinical calcium 20100701

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].

  Clinical calcium 20100701

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].

  Clinical calcium 20100701

• Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100601

• Amino terminal cleavage of PTH(1-84) to PTH(7-84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients.

  Clinical and experimental nephrology 20100601

• Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.

  American journal of physiology. Renal physiology 20100601

• Do calcimimetics directly alter bone remodeling?

  American journal of physiology. Renal physiology 20100601

• New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

  Pediatric nephrology (Berlin, Germany) 20100401

• [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].

  Nephrologie & therapeutique 20100401

• Treatment with calcimimetics in kidney transplantation.

  Transplantation reviews (Orlando, Fla.) 20100401

• Parathyroid gland ultrasound patterns and biochemical findings after one-year cinacalcet treatment for advanced secondary hyperparathyroidism.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20100401

• Cinacalcet in the treatment of intractable hypercalcemia following two neck exploration surgeries for primary hyperparathyroidism.

  Southern medical journal 20100301

• Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100201

• [Calcimimetic drugs in nondialyzed patients].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20100201

• Involvement of the calcium-sensing receptor in human taste perception.

  The Journal of biological chemistry 20100108

• Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.

  Journal of bone and mineral metabolism 20100101

• Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.

  Hemodialysis international. International Symposium on Home Hemodialysis 20100101

• Middle-term use of Cinacalcet in paediatric dialysis patients.

  Pediatric nephrology (Berlin, Germany) 20100101

• Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size.

  Nephron. Clinical practice 20100101

• Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

  Clinical journal of the American Society of Nephrology : CJASN 20100101

• Parathyroid gland: cinacalcet-can it control hypercalcemia?

  Nature reviews. Endocrinology 20100101

• Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

  The oncologist 20100101

• Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20100101

• Medical management of primary hyperparathyroidism with concomitant multiple myeloma.

  Internal medicine (Tokyo, Japan) 20100101

• Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.

  Nephron. Clinical practice 20100101

• Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation.

  American journal of nephrology 20100101

• [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101

• Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.

  Hormones (Athens, Greece) 20100101

• Cinacalcet - clinical and laboratory effectiveness, concomitant treatment patterns and treatment cost: could we do better and how?

  Kidney & blood pressure research 20100101

• [Ultrasound parameter-based response to treatment with new drugs for secondary hyperparathyroidism: a retrospective analysis in a single dialysis center].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20100101

• Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.

  PharmacoEconomics 20100101

• Management of skeletal health in patients with asymptomatic primary hyperparathyroidism.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

• Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.

  The Journal of clinical endocrinology and metabolism 20091201

• Is it my calcium, Doctor?

  Archives of disease in childhood. Education and practice edition 20091201

• [Patient with chronic kidney disease and primary or tertiary hyperparathyroidism--case report].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20091201

• Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism.

  Nuclear medicine communications 20091101

• Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells.

  American journal of physiology. Regulatory, integrative and comparative physiology 20091101

• [Management of serum calcium with cinacelet in parathyroid cancer].

  Ugeskrift for laeger 20091005

• Emerging roles of cinacalcet hydrochloride in the management of CKD-MBD.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Clinical issues regarding cinacalcet hydrochloride in Japan.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Does cinacalcet improve the prognosis of dialysis patients?

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Management of mineral and bone disorder in chronic kidney disease: quo vadis?

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Cinacalcet in hyperfunctioning parathyroid diseases.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091001

• Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090901

• Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.

  Clinical journal of the American Society of Nephrology : CJASN 20090901

• Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.

  Clinical journal of the American Society of Nephrology : CJASN 20090901

• Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients.

  Clinical nephrology 20090901

• Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet.

  The American surgeon 20090901

• The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.

  European journal of pharmacology 20090815

• [Medical treatment of patients with primary hyperparathyroidism].

  Ugeskrift for laeger 20090810

• Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801

• Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

  The Journal of clinical endocrinology and metabolism 20090801

• Cinacalcet-induced leukocytoclastic vasculitis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090801

• Cinacalcet for hyperparathyroidism in pregnancy and puerperium.

  Journal of pediatric endocrinology & metabolism : JPEM 20090801

• Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the 'U'.

  Clinical nephrology 20090601

• Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?

  Nature reviews. Nephrology 20090601

• [Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].

  Clinical calcium 20090401

• [Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].

  Clinical calcium 20090401

• [Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].

  Clinical calcium 20090401

• [Medical treatment of primary hyperparathyroidism: role of calcimimetics].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20090401

• Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20090301

• Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301

• Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301

• Treatable dropped head syndrome in hyperparathyroidism.

  Muscle & nerve 20090301

• Update on the treatment of chronic kidney disease-mineral and bone disorder.

  Journal of renal care 20090301

• Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.

  Clinical journal of the American Society of Nephrology : CJASN 20090301

• [Primary hyperparathyroidism. An alternative to the surgery].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20090301

• [Calciphylaxis treated by cinacalcet: a medical alternative to parathyroidectomy].

  La Revue de medecine interne 20090201

• Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.

  American journal of nephrology 20090201

• Regression of parathyroid gland swelling by treatment with cinacalcet.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201

• A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090201

• Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.

  Clinical journal of the American Society of Nephrology : CJASN 20090201

• Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090201

• Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

  The Journal of clinical endocrinology and metabolism 20090201

• Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.

  Clinical nephrology 20090201

• Caring for chronic kidney disease patients: focus on mineral and bone disorders.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20090201

• Calcimimetics in the chronic kidney disease-mineral and bone disorder.

  The International journal of artificial organs 20090201

• Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090101

• Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.

  Clinical journal of the American Society of Nephrology : CJASN 20090101

• The new role of calcimimetics as vasculotropic agents.

  Kidney international 20090101

• Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.

  Nephron. Clinical practice 20090101

• [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101

• Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

  Clinical pharmacokinetics 20090101

• Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.

  Drugs & aging 20090101

• Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.

  Transplantation proceedings 20090101

• Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism.

  Transplantation proceedings 20090101

• Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure.

  Transplantation proceedings 20090101

• Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism.

  Transplantation proceedings 20090101

• Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.

  Transplantation proceedings 20090101

• [Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101

• Sodium thiosulfate, bisphosphonates, and cinacalcet for calciphylaxis.

  CANNT journal = Journal ACITN 20090101

• Cinacalcet reduces the set point of the PTH-calcium curve.

  Journal of the American Society of Nephrology : JASN 20081201

• Calcimimetics, calcium set point and calcium balance.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

• A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.

  European journal of endocrinology 20081201

• Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20081201

• Cinacalcet: pharmacological and clinical aspects.

  Expert opinion on drug metabolism & toxicology 20081201

• [Diagnosis and therapy of primary hyperparathyreoidism].

  MMW Fortschritte der Medizin 20081106

• Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081101

• Cinacalcet suppresses calcification of the aorta and heart in uremic rats.

  Kidney international 20081101

• Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

  Clinical journal of the American Society of Nephrology : CJASN 20081101

• Effects of treatment of renal osteodystrophy on bone histology.

  Clinical journal of the American Society of Nephrology : CJASN 20081101

• Successful off-label use of cinacalcet HCl after standard therapy failure in a young man with pseudohypoparathyroidism Type 1b and vitamin D intoxication sequelae.

  Clinical nephrology 20081101

• [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20081101

• Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation.

  Transplantation 20081015

• Cinacalcet is efficacious in pediatric dialysis patients.

  Pediatric nephrology (Berlin, Germany) 20081001

• Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.

  Pediatric nephrology (Berlin, Germany) 20081001

• Calcimimetics in CKD-results from recent clinical studies.

  Pediatric nephrology (Berlin, Germany) 20081001

• Human chorionic gonadotropin measurements in parathyroid carcinoma.

  European journal of endocrinology 20081001

• Optimal TARGETs for cardiovascular safety and benefit in ESRD.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001

• 19th Annual Meeting of the Japanese Society for Kidney Bone Disease.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Clinical study of cinacalcet in Japan.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Changes in interventional treatment--from the viewpoint of percutaneous ethanol injection therapy.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Change in coronary artery calcification score due to cinacalcet hydrochloride administration.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20081001

• Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901

• Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901

• Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy.

  Clinical nephrology 20080901

• Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.

  Transplantation 20080815

• Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.

  Kidney international 20080801

• Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080801

• [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].

  Deutsche medizinische Wochenschrift (1946) 20080801

• Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study.

  Clinical nephrology 20080801

• Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism.

  The International journal of artificial organs 20080801

• Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080701

• Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

  Nature clinical practice. Nephrology 20080701

• Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

  Nature clinical practice. Nephrology 20080701

• Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080701

• Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080701

• Surgical treatment of persistent hyperparathyroidism after renal transplantation.

  Annals of surgery 20080701

• A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.

  Nature clinical practice. Endocrinology & metabolism 20080601

• Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

  Clinical journal of the American Society of Nephrology : CJASN 20080501

• Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

  Clinical journal of the American Society of Nephrology : CJASN 20080501

• Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401

• Cinacalcet, fetuin-A and interleukin-6.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401

• Cinacalcet: benefit and cost.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401

• Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20080401

• Cinacalcet for the treatment of primary hyperparathyroidism.

  Metabolism: clinical and experimental 20080401

• New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.

  Expert opinion on pharmacotherapy 20080401

• Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080401

• Massive soft tissue calcifications and cinacalcet.

  The Journal of clinical endocrinology and metabolism 20080401

• New approaches to treatment of secondary hyperparathyroidism.

  Current opinion in investigational drugs (London, England : 2000) 20080401

• An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

  Clinical nephrology 20080401

• [Cinacalcet in the therapy of secondary hyperparathyroidism--own experiences].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20080401

• [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].

  Revue medicale suisse 20080305

• Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080301

• Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.

  Expert opinion on pharmacotherapy 20080301

• Cinacalcet improves bone mineral density in a renal transplant recipient with persistent hyperparathyroidism.

  Clinical nephrology 20080301

• Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia.

  Clinical endocrinology 20080201

• Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080201

• [Treatment of secondary hyperparathyroidism in dialysis: Report of a case-study of treatment failure].

  Nephrologie & therapeutique 20080201

• Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism.

  The American journal of the medical sciences 20080201

• Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

  The American journal of the medical sciences 20080201

• Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• Can calcimimetics inhibit nodular hyperplasia of parathyroid glands?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].

  Clinical calcium 20080101

• [Basic and clinical aspects of calcimimetics. The JSDT guideline and cinacalcet hydrochloride].

  Clinical calcium 20080101

• [Basic and clinical aspects of calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation].

  Clinical calcium 20080101

• [Basic and clinical aspects of calcimimetics. Calcimimetics from the viewpoint of medical cost].

  Clinical calcium 20080101

• [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].

  Clinical calcium 20080101

• [Basic and clinical aspects of calcimimetics. Calcimimetics and vascular calcification].

  Clinical calcium 20080101

• Cinacalcet as first-line treatment for calciphylaxis.

  Acta dermato-venereologica 20080101

• The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.

  Clinical journal of the American Society of Nephrology : CJASN 20080101

• Recent updates on the calcium-sensing receptor as a drug target.

  Current medicinal chemistry 20080101

• Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

• Diagnostic fine-needle aspiration biopsy of an intrathyroidal parathyroid gland and subsequent eucalcemia in a patient with primary hyperparathyroidism.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

• Preventive measures and new pharmacological approaches of calcium and phosphate disorders.

  Contributions to nephrology 20080101

• Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.

  Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20080101

• Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

  Internal medicine (Tokyo, Japan) 20080101

• Calciphylaxis of the breast: a rare disease in the differential diagnosis of breast cancer.

  Acta dermatovenerologica Croatica : ADC 20080101

• [Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.

  Drugs in R&D 20080101

• Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.

  Clinical drug investigation 20080101

• [Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• [Clinical advances in vascular calcification].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• The role of calcimimetics in the treatment of hyperparathyroidism.

  European journal of clinical investigation 20071201

• [Parathyroid and bone. Calcimimetics and bone metabolism].

  Clinical calcium 20071201

• CKD-MBD: impact on management of kidney disease.

  Clinical and experimental nephrology 20071201

• Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report.

  Transplantation proceedings 20071201

• Cost-utility analysis of cinacalcet in addition to standard of care in the UK.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071101

• Cinacalcet, paricalcitol, or both?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

• Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet.

  The Journal of pharmacology and experimental therapeutics 20071001

• Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.

  Journal of clinical pharmacology 20071001

• Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.

  The Journal of clinical endocrinology and metabolism 20071001

• Calcimimetic, AMG 073, induces relaxation on isolated rat aorta.

  Vascular pharmacology 20071001

• Expression and function of the calcium-sensing receptor in juxtaglomerular cells.

  Hypertension (Dallas, Tex. : 1979) 20071001

• Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient.

  Clinical nephrology 20071001

• Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070901

• A calcium-receptor agonist induces gustatory neural responses in bullfrogs.

  Cellular and molecular neurobiology 20070901

• Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

  Clinical journal of the American Society of Nephrology : CJASN 20070901

• Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient.

  The American journal of medicine 20070901

• Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism.

  Transplantation proceedings 20070901

• Cinacalcet modifies the pH of solutions in vitro: possible implications for gastro-intestinal side effects in vivo.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801

• Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801

• An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma.

  Clinical chemistry 20070801

• Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070701

• Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070701

• Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.

  Clinical nephrology 20070701

• 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers.

  Clinical nephrology 20070701

• Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070601

• Cinacalcet in the management of tumor-induced osteomalacia.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070601

• Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20070601

• Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

  Journal of managed care pharmacy : JMCP 20070601

• The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501

• [Reader's letter on Marcus Meissner, Jens, Gille, Roland Kaufmann. Calciphylaxis: no therapeutic concepts for a poorly understood syndrome?].

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20070501

• The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20070501

• [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].

  Clinical calcium 20070501

• Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation.

  Transplantation 20070315

• Lithium hypercalcemia, hyperparathyroidism, and cinacalcet.

  Kidney international 20070301

• Nonsurgical management of primary hyperparathyroidism.

  Mayo Clinic proceedings 20070301

• Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis.

  Clinical nephrology 20070301

• Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.

  European journal of clinical pharmacology 20070201

• Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070201

• Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070201

• Cinacalcet for the treatment of calciphylaxis.

  Archives of dermatology 20070201

• Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.

  Clinical therapeutics 20070201

• Management of chronic kidney disease mineral-bone disorder.

  Advances in chronic kidney disease 20070101

• [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].

  Clinical calcium 20070101

• Cinacalcet-induced hungry bone syndrome.

  Seminars in dialysis 20070101

• Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.

  Drugs in R&D 20070101

• Final Word: The binders wars 2007-2017: 'The truth is out there somewhere...'.

  Seminars in dialysis 20070101

• Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism.

  American journal of nephrology 20070101

• The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals.

  American journal of therapeutics 20070101

• Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.

  Clinical pharmacokinetics 20070101

• Treating hyperparathyroidism with cinacalcet HCl (Sensipar).

  Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20070101

• [New management of phosphocalcic abnormalities in dialysis patient].

  Revue medicale de Liege 20070101

• Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

  Drugs 20070101

• Calcium sensing receptor activators: calcimimetics.

  Current medicinal chemistry 20070101

• [When evidence does not correspond to cost-effectiveness].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20070101

• [K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101

• Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.

  Clinical chemistry 20061201

• Cinacalcet as an adjunct in the successful treatment of calciphylaxis.

  The British journal of dermatology 20061201

• Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.

  Journal of the American Society of Nephrology : JASN 20061201

• Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet.

  Transplantation proceedings 20061201

• Calciphylaxis: no therapeutic concepts for a poorly understood syndrome?

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20061201

• Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism.

  Surgery 20061201

• Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20061101

• [Hypercalcemia (with treatment)].

  La Revue du praticien 20061031

• Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20061001

• Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease.

  Expert opinion on pharmacotherapy 20061001

• Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.

  Hemodialysis international. International Symposium on Home Hemodialysis 20061001

• Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.

  Transplantation 20060915

• The diagnosis and management of asymptomatic primary hyperparathyroidism.

  Nature clinical practice. Endocrinology & metabolism 20060901

• [Calcium receptor/calcium-sensing receptor].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060901

• Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor.

  Journal of internal medicine 20060801

• Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20060801

• Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701

• Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20060701

• Parathyroid cancer.

  Surgical oncology clinics of North America 20060701

• [Secondary hyperparathyroidism].

  Nihon rinsho. Japanese journal of clinical medicine 20060628

• Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060601

• Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060601

• Drug Insight: renal indications of calcimimetics.

  Nature clinical practice. Nephrology 20060601

• Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats.

  Kidney international 20060501

• Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060501

• Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.

  Clinical nephrology 20060501

• A case of parathyroid carcinoma with hypercalcemia responsive to cinacalcet therapy.

  Nature clinical practice. Endocrinology & metabolism 20060501

• Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?

  Nature clinical practice. Nephrology 20060501

• The management of secondary hyperparathyroidism.

  Annales d'endocrinologie 20060401

• Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.

  Pharmacology & therapeutics 20060301

• Therapeutic failure of cinacalcet in a renal transplant patient.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060301

• Racial differences in response to cinacalcet as a treatment for uremic hyperparathyroidism.

  Kidney international 20060301

• Calcium, calcimimetics and clinical outcomes.

  Clinical journal of the American Society of Nephrology : CJASN 20060301

• Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.

  Clinical journal of the American Society of Nephrology : CJASN 20060301

• Improvement in hypercalcemia with cinacalcet after kidney transplantation.

  Clinical journal of the American Society of Nephrology : CJASN 20060301

• Cinacalcet and vascular calcifications induced by calcitriol.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060201

• [The latest developments in endocrinology 2004/2005].

  Medizinische Klinik (Munich, Germany : 1983) 20060115

• [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].

  Ugeskrift for laeger 20060103

• Calcimimetics for predialysis patients?

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060101

• Looking at calcimimetics impact on hypercalcemia of immobilization: hypotheses and a case study.

  Hemodialysis international. International Symposium on Home Hemodialysis 20060101

• [Calcimimetics].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20060101

• Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.

  Journal of bone and mineral metabolism 20060101

• [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].

  Przeglad lekarski 20060101

• Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?

  Journal of nephrology 20060101

• Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.

  Clinical laboratory 20060101

• Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051201

• [How to slow down parathyroid hormone (PTH) secretion without the risk of inducing an adynamic bone disease].

  Nephrologie & therapeutique 20051201

• [Chronic kidney disease].

  Medizinische Klinik (Munich, Germany : 1983) 20051115

• Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.

  Clinical therapeutics 20051101

• Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051001

• Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.

  Kidney international 20051001

• Immunosuppressive and calcimimetic drug-drug interactions.

  Kidney international 20051001

• Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.

  European journal of endocrinology 20051001

• Parathyroidectomy in the calcimimetic era.

  Nephrology (Carlton, Vic.) 20051001

• [Calcimimetics, mechanisms of action and therapeutic applications].

  Presse medicale (Paris, France : 1983) 20050910

• First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

  Kidney international 20050901

• [Management of secondary hyperparathyroidism].

  Clinical calcium 20050901

• 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050701

• Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?

  Current opinion in nephrology and hypertension 20050701

• Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050701

• The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050701

• Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.

  Kidney international. Supplement 20050701

• Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050701

• Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050601

• Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.

  Kidney international. Supplement 20050601

• Calcimimetics and calcilytics--fooling the calcium receptor.

  Lancet (London, England) 20050601

• High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism.

  Kidney international 20050501

• Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis.

  Pharmacotherapy 20050501

• [Calcimimetics--a new treatment for hyperparathyroidism?].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20050501

• The latest findings in basic and clinical nephrology science.

  Drug news & perspectives 20050401

• Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.

  Pediatric nephrology (Berlin, Germany) 20050301

• Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

  Journal of the American Society of Nephrology : JASN 20050301

• Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.

  Journal of pharmacological sciences 20050301

• Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.

  Expert opinion on pharmacotherapy 20050301

• Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

  Kidney international 20050201

• Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

  Kidney international 20050201

• New drugs 05, part I.

  Nursing 20050201

• Challenges in the therapy of secondary hyperparathyroidism.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201

• Calcimimetics--fooling the calcium receptor.

  Pediatric nephrology (Berlin, Germany) 20050101

• Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

  The Journal of clinical endocrinology and metabolism 20050101

• Cinacalcet hydrochloride.

  Drugs 20050101

• Cinacalcet hydrochloride: a viewpoint by Pablo Ureña Torres.

  Drugs 20050101

• Cinacalcet hydrochloride: a viewpoint by Sharon M. Moe.

  Drugs 20050101

• [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].

  Clinical calcium 20050101

• New prospects for the management of renal bone disease.

  Nephron. Clinical practice 20050101

• Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.

  Pharmacogenetics and genomics 20050101

• No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).

  Clinical pharmacokinetics 20050101

• The role of cinacalcet in treating secondary hyperparathyroidism.

  Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20050101

• [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• Cinacalcet cost and utility in dialysis patients.

  Seminars in dialysis 20050101

• Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.

  Drug metabolism and disposition: the biological fate of chemicals 20041201

• Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20041201

• Clinical effects of calcimimetics in hyperparathyroidism.

  Journal of musculoskeletal & neuronal interactions 20041201

• Summary--calcium receptors: potential targets for novel treatments for skeletal disease.

  Journal of musculoskeletal & neuronal interactions 20041201

• Secondary hyperparathyroidism: review of the disease and its treatment.

  Clinical therapeutics 20041201

• Calcimimetics and the treatment of primary and secondary hyperparathyroidism.

  The Annals of pharmacotherapy 20041101

• [New aspects in the management of renal osteodystrophy].

  Polskie Archiwum Medycyny Wewnetrznej 20041001

• Cinacalcet (sensipar).

  The Medical letter on drugs and therapeutics 20040927

• The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials.

  Kidney international. Supplement 20040901

• Calcimimetic agents for the treatment of secondary hyperparathyroidism.

  Seminars in nephrology 20040901

• [Prophylaxis and treatment of adynamic bone].

  Clinical calcium 20040901

• [Significance of point of no return in therapeutic strategy for treatment of renal osteodystrophy; from histopathological findings].

  Clinical calcium 20040901

• Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040801

• Modulation and action of the calcium-sensing receptor.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040801

• Clinical experience with cinacalcet HCl.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040801

• Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.

  The New England journal of medicine 20040708

• Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.

  The New England journal of medicine 20040708

• The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.

  British journal of clinical pharmacology 20040601

• [Clinical application of calcimimetics].

  Clinical calcium 20040501

• New drugs and dosage forms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040415

• Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

  The New England journal of medicine 20040408

• Fooling the parathyroid gland--will there be health benefits?

  The New England journal of medicine 20040408

• Calcium agonists in hyperparathyroidism.

  Expert opinion on investigational drugs 20040301

• Calcimimetic and calcilytic drugs: just for parathyroid cells?

  Cell calcium 20040301

• Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.

  The Journal of pharmacology and experimental therapeutics 20040201

• Calcimimetics versus vitamin D: what are their relative roles?

  Blood purification 20040101

• Update in nephrology. Highlights from the 36th Annual Meeting of the American Society of Nephrology.

  Drugs of today (Barcelona, Spain : 1998) 20040101

• First treatment for serious complications of kidney disease, parathyroid cancer.

  FDA consumer 20040101

• New agents for the treatment of renal osteodystrophy.

  CANNT journal = Journal ACITN 20040101

• Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

  Pediatric nephrology (Berlin, Germany) 20031201

• Calcimetic AMG 073 at 50 and 100 mg per day.

  Kidney international 20031201

• The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.

  The Journal of clinical endocrinology and metabolism 20031201

• Molecule of the month. Cinacalcet hydrochloride.

  Drug news & perspectives 20030901

• Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.

  Expert opinion on investigational drugs 20030801

• Cinacalcet hydrochloride (Amgen).

  IDrugs : the investigational drugs journal 20030601

• The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

  Journal of the American Society of Nephrology : JASN 20030301

• The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.

  Kidney international 20030101

• Cinacalcet: Amg 073, calcimimetics--Amgen/NPS Pharmaceuticals.

  Drugs in R&D 20030101

• Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.

  Drugs in R&D 20030101

• In vitro studies with the calcimimetic, cinacalcet HCl, on normal human adult osteoblastic and osteoclastic cells.

  Critical reviews in eukaryotic gene expression 20030101

• [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].

  Przeglad lekarski 20030101

• Calcimimetics: therapeutic potential in hyperparathyroidism.

  Current opinion in pharmacology 20021201

• The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

  Journal of the American Society of Nephrology : JASN 20020401